The evolving landscape of metastatic renal cell carcinoma.
The treatment paradigm in metastatic renal cell carcinoma (mRCC) has evolved over the last 5 years. There are now seven approved targeted therapies against the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The use of targeted therapy, sequences, combinations, and investigational compounds will be discussed. Prognostic and predictive tools are detailed, although much work must be done to find predictive biomarkers in an effort to individualize therapy for patients.
From the Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA.
Daniel Y C
DY
Heng
From the Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA.
Toni K
TK
Choueiri